ArticleOncogene2017
Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma.
Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- CX3CR1-Dependent Macrophages Drive Ovarian Cancer Progression Through MMP-2 and TGF-β Production.Cancers · 2026Article
- Article
- The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer.Neoplasia (New York, N.Y.) · 2025Article
- Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges.Biomolecules · 2024Review
- Dual Targeting of CXCancers · 2024Article
- Immune Cell Migration to Cancer.Cells · 2024Review
- A Recipe for Successful Metastasis: Transition and Migratory Modes of Ovarian Cancer Cells.Cancers · 2024Review
- CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity.Frontiers in immunology · 2024Article
- Targeting Microtubule-Associated Protein Tau in Chemotherapy-Resistant Models of High-Grade Serous Ovarian Carcinoma.Cancers · 2022Article
- Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Review
- Chemokine expression in patients with ovarian cancer or benign ovarian tumors.Archives of medical science : AMS · 2022Article
- Effect ofFrontiers in genetics · 2022Article
- Site-specific metastasis: A cooperation between cancer cells and the metastatic microenvironment.International journal of cancer · 2021Review
- CXJournal of cellular and molecular medicine · 2021Article
- Article
- Fractalkine/CX3CL1 in Neoplastic Processes.International journal of molecular sciences · 2020Review
- Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors.Cancer metastasis reviews · 2019Review
- Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma.Cancers · 2018Review
- CD206-positive myeloid cells bind galectin-9 and promote a tumor-supportive microenvironment.The Journal of pathology · 2018Article
- Regulation of DNA damage repair and lipid uptake by CXOncogenesis · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Epithelial ovarian carcinoma is the most common cause of death from gynecologic cancers largely due to advanced, relapsed and chemotherapy-resistant peritoneal metastasis, which is refractory to the currently used treatment approaches. Mechanisms supporting advanced and relapsed peritoneal metastasis are largely unknown, precluding development of more effective targeted therapies. In this study, we investigated the function of a potentially targetable fractalkine axis in the formation and the development of advanced and relapsed peritoneal metastasis and its impact on patients' outcomes. Our mouse model studies support a role for the fractalkine receptor (CX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.